Danish biotech group hires international CEO
Five year old Acesion Pharma is getting ready to enter the clinical stage with its first drug next year, and the group is thus professionalizing by bringing a new CEO from abroad.
BY LOUISE WENDT JENSEN
"This is a natural development, because we’re ready to start development of our first drug. As such, we need a more development and commercially minded Chief Executive," explains Ingelise Saunders, Chairwoman of Acesion Pharma, which last week announced that the company appointed a new CEO on April 1st.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Boehringer appoints new chief of Danish unit
For abonnenter
Novo Seeds looking to expand its investment team
For abonnenter
Novo Seeds to invest more in medtech
For abonnenter
